Incytevs.Regeneron
INCY vs REGN · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Regeneron is about 3.0× larger than Incyte by market cap; year to date, Incyte leads (+18.2% vs −13.9%).
Side by side
| INCY | REGN | |
|---|---|---|
| Market cap | $23.1B | $69.7B |
| Price | $116.71 | $664.52 |
| Today | −1.5% | −0.5% |
| Return YTD | +18.2% | −13.9% |
| Return 1Y | +65.9% | +18.7% |
| P/E | 16.1 | 15.7 |
| P/S | 4.3 | 4.7 |
| P/B | 4.1 | 2.2 |
Data as of 2026-07-11 · updates daily after U.S. close
The two companies
RegeneronREGN
American biotech company focused on antibody-based medicines in ophthalmology, immunology and oncology.
Full REGN profile →More comparisons in Biotech & innovation
See where INCY and REGN sit in the full Medicine, pharma & life science map — every segment from suppliers to end markets.Open the Life science value chain →